1. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Issue 12 (December 2014) Authors: Mulligan, Stephen P.; Karlsson, Karin; Strömberg, Mats; Jønsson, Viggo; Gill, Devinder; Hammerström, Jens; Hertzberg, Mark; McLennan, Roger; Uggla, Bertil; Norman, John; Wallvik, Jonas; Sundström, Gunnel; Johansson, Hemming; Brandberg, Yvonne; Liliemark, Jan; Juliusson, Gunnar; for the Scandinavi... Journal: Leukemia & lymphoma Issue: Volume 55:Issue 12(2014:Dec.) Page Start: 2769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs. (August 2017) Authors: Sandman, Lars; Liliemark, Jan Journal: Seminars in cancer biology Issue: Volume 45(2017) Page Start: 58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Outcomes associated with higher relational continuity in the treatment of persons with asthma or chronic obstructive pulmonary disease: A systematic review. (July 2022) Authors: Lytsy, Per; Engström, Sven; Ekstedt, Mirjam; Engström, Ingemar; Hansson, Lars; Ali, Lilas; Fredriksson, Maja Kärrman; Liliemark, Jan; Berg, Jenny Journal: EClinicalMedicine Issue: Volume 49(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Withholding and withdrawing treatment for cost‐effectiveness reasons: Are they ethically on par?. (7th December 2018) Authors: Sandman, Lars; Liliemark, Jan Journal: Bioethics Issue: Volume 33:Number 2(2019) Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗